Valuation: COSMO Pharmaceuticals SA

Market Cap 951M 1.1B 899M 816M 1.53B 105B 1.54B 10.73B 4.15B 53.41B 4.12B 4.03B 170B P/E 2026 *
823x
P/E 2027 * 19.1x
Enterprise Value 923M 1.06B 872M 792M 1.48B 102B 1.49B 10.41B 4.02B 51.81B 4B 3.91B 165B EV / Sales 2026 *
8.68x
EV / Sales 2027 * 5.24x
Free-Float
40.52%
Yield 2026 *
3.84%
Yield 2027 * 4.08%

Last Transcript: COSMO Pharmaceuticals SA

Manager TitleAgeSince
Chief Executive Officer 52 23/05/2024
Director of Finance/CFO - 10/11/2024
Chief Tech/Sci/R&D Officer 53 31/12/2008
Director TitleAgeSince
Chairman 71 31/12/2013
Director/Board Member 71 31/03/2012
Director/Board Member 54 23/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+1.21%+48.79%+97.65% 1,013B
+0.03%+0.07%+51.47%+65.55% 644B
-0.20%+4.62%+21.39%+72.57% 465B
+0.53%+4.26%+40.29%+38.70% 352B
+0.39%+2.35%+17.96%+23.87% 264B
+0.17%+4.17%+6.96%+10.93% 253B
+0.19%-3.81%+37.81%+44.35% 203B
-1.20%-5.64%-24.09%-59.10% 188B
+0.94%+1.39%+33.21%+95.16% 181B
Average +0.11%-0.62%+25.98%+43.30% 395.97B
Weighted average by Cap. +0.11%+0.32%+34.33%+59.67%

Financials

2026 *2027 *
Net sales 106M 123M 100M 91.21M 171M 11.77B 172M 1.2B 463M 5.97B 461M 451M 19.02B 176M 203M 166M 151M 283M 19.48B 285M 1.99B 767M 9.88B 763M 746M 31.5B
Net income 1.27M 1.47M 1.2M 1.09M 2.05M 141M 2.06M 14.38M 5.56M 71.57M 5.53M 5.4M 228M 49.6M 57.24M 46.88M 42.56M 79.77M 5.49B 80.25M 560M 216M 2.78B 215M 210M 8.88B
Net Debt -28.5M -32.89M -26.94M -24.45M -45.83M -3.15B -46.11M -322M -124M -1.6B -124M -121M -5.1B -28.81M -33.24M -27.23M -24.72M -46.32M -3.19B -46.6M -325M -126M -1.62B -125M -122M -5.16B
Logo COSMO Pharmaceuticals SA
Cosmo N.V. formerly known as COSMO Pharmaceuticals N.V. is an Ireland based pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!